お知らせ • Sep 23
IMV Inc. Files Form 15 IMV Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended. お知らせ • Jul 08
Nasdaq to Delist the Common Shares of IMV Nasdaq announced on July 06, 2023 that it will delist the common shares of IMV Inc. The company’s securities were suspended on May 11, 2023, and have not traded on Nasdaq since that time. お知らせ • May 12
IMV Inc.(OTCPK:IMVI.Q) dropped from NASDAQ Composite Index IMV Inc. has been added to NASDAQ Composite Index (^COMP). お知らせ • May 09
IMV Receives Nasdaq Delisting Notice IMV Inc. (the “Company” or “IMV”) announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”). The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s common shares from listing on the Nasdaq. IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). お知らせ • Feb 14
IMV Inc. Presents Positive Initial Results from the MVP-S Phase 2B Vitalize Trial IMV Inc. announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma ("r/r DLBCL"). Overall Response Rate ("ORR") will be communicated when the totality of stage one data are available for definitive assessment. Board Change • Jan 13
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Saman Maleki was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. お知らせ • Jan 09
IMV Inc. Announces Board Changes IMV Inc. announced the appointment of Shabnam Kazmi to the Board of Directors. Ms. Kazmi is an experienced CEO and Founder with over 30 years experience in top-tier global biopharma companies such as Bristol-Myers Squibb, Sanofi and Otsuka America Pharmaceuticals. She has deep expertise in oncology, having launched and managed multiple top tier products across both solid tumors and hematology. She currently serves as the CEO of Asellus Ventures, a healthcare advisory and investment firm. She has led multiple global joint ventures and successfully managed large complex projects across 75 countries with a focus on managing risk and creating asset value. Ms. Kazmi has consistently achieved outstanding financial results and growth in value for shareholders by managing $1B+ P&Ls, developing innovative strategies, M&A, building highly talented teams, raising capital, and successfully launching and commercializing oncology products for the treatment of both solid tumors and hematology. Her passion for patients and over 20 years of board service has led to multiple awards from cancer patient groups, and she currently serves as a Board Member of the Prevent Cancer Foundation. Ms. Kazmi has a Bachelor’s degree in Economics and Biochemistry from Smith College and an MBA from Harvard Business School. Ms. Kazmi’s appointment follows the decision of Ms. Julia P. Gregory who has served on IMV's Board of Directors since June 2018, to retire from the Board of Directors. Board Change • Aug 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Jul 05
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Senior VP of Finance, Corporate Secretary & Director Brittany Davison was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 18
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: US$0.49 loss per share (down from US$0.45 loss in FY 2020). Net loss: US$36.6m (loss widened 34% from FY 2020). Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 609%, compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Executive Departure • Aug 05
CEO & Director Frederic Ors has left the company During their tenure, earnings grew by 32% annually compared to the industry average of 23%. On the 1st of August, Frederic Ors left the company after 5.3 in the role. As of March 2021, Frederic still personally held 301.47k shares (US$1.0m worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Frederic's leadership, the company delivered a total shareholder return of 21%. Board Change • Jul 31
High number of new directors Independent Director Kyle Kuvalanka was the last director to join the board, commencing their role in 2021. Recent Insider Transactions • Jul 25
CEO & Director recently bought US$147k worth of stock On the 23rd of July, Frederic Ors bought around 100k shares on-market at roughly US$1.47 per share. This was the largest purchase by an insider in the last 3 months. Frederic has been a buyer over the last 12 months, purchasing a net total of US$195k worth in shares. Executive Departure • Jun 15
Chief Medical Officer Joanne Schindler has left the company On the 11th of June, Joanne Schindler's tenure as Chief Medical Officer ended after 1.6 years in the role. We don't have any record of a personal shareholding under Joanne's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Apr 07
Independent Director has left the company On the 1st of April, Wayne Pisano's tenure as Independent Director ended after 9.5 years in the role. As of December 2020, Wayne personally held 77.28k shares (US$238k worth at the time). Wayne is the only executive to leave the company over the last 12 months. Reported Earnings • Mar 19
Full year 2020 earnings released: CA$0.58 loss per share (vs CA$0.55 loss in FY 2019) Full year 2020 results: Net loss: CA$34.9m (loss widened 27% from FY 2019). Products in clinical trials Phase I: 1 Phase II: 7 Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 05
New 90-day high: US$4.36 The company is up 18% from its price of US$3.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$16.30 per share. Is New 90 Day High Low • Dec 19
New 90-day low: US$3.13 The company is down 37% from its price of US$4.97 on 18 September 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$13.97 per share. Analyst Estimate Surprise Post Earnings • Nov 13
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 33%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Is New 90 Day High Low • Oct 27
New 90-day low: US$3.15 The company is down 36% from its price of US$4.95 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.95 per share. Is New 90 Day High Low • Oct 12
New 90-day low: US$3.85 The company is down 17% from its price of US$4.63 on 14 July 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$12.25 per share.